AMAP-102

{{Infobox drug

| drug_name =

| image =

| width =

| caption =

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| licence_CA =

| licence_EU =

| DailyMedID =

| licence_US =

| pregnancy_AU =

| pregnancy_category =

| dependency_liability =

| addiction_liability =

| routes_of_administration = Oral

| class = Serotonin 5-HT_2B receptor antagonist; Serotonin 5-HT_2C receptor antagonist

| ATC_prefix =

| ATC_suffix =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number =

| CAS_supplemental =

| PubChem =

| PubChemSubstance =

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID =

| UNII =

| KEGG =

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = AMAP102

| IUPAC_name =

| C= | H= | N= | O=

| SMILES =

| StdInChI =

| StdInChIKey =

}}

AMAP-102 is a serotonin 5-HT_2B and 5-HT_2C receptor antagonist which is or was under development for the treatment of musculoskeletal pain and rheumatoid arthritis.{{cite journal | vauthors = Wang Q, Zhou Y, Huang J, Huang N | title = Structure, Function, and Pharmaceutical Ligands of 5-Hydroxytryptamine 2B Receptor | journal = Pharmaceuticals (Basel) | volume = 14 | issue = 2 | date = January 2021 | page = 76 | pmid = 33498477 | pmc = 7909583 | doi = 10.3390/ph14020076 | doi-access = free | url = | quote = }}{{cite web | title=AMAP 102 | website=AdisInsight | date=4 November 2017 | url=https://adisinsight.springer.com/drugs/800031110 | access-date=14 January 2025}}{{cite web | title=Delving into the Latest Updates on AMAP-102 with Synapse | website=Synapse | date=21 November 2024 | url=https://synapse.patsnap.com/drug/5a6e89f25d8d4016838c52e05dc502a2 | access-date=14 January 2025}} It is taken by mouth.

The drug is or was under development by AnaMar AB. A phase 1 clinical trial was completed in 2009 and the results of a phase 2 trial were reported in 2014. It failed to reduce inflammatory pain in people with osteoarthritis in this trial and its development was said to have been discontinued. However, the drug is still listed as being in active development as of January 2025. The chemical structure of AMAP-102 does not appear to have been disclosed.